Monalizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Monalizumab
Accession Number
DB12824
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Monalizumab has been used in trials studying the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
IPH2201
Categories
Not Available
UNII
3ZXZ2V0588
CAS number
1228763-95-8

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911389
Wikipedia
Monalizumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedOtherGynecologic Cancers1
1RecruitingTreatmentMalignancies, Hematologic1
1, 2RecruitingTreatmentNeoplasms, Head and Neck1
1, 2TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL)1
1, 2TerminatedTreatmentSquamous Cell Carcinoma of the Oral Cavity1
1, 2WithdrawnTreatmentAdenocarcinoma of the Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Squamous Cell Carcinoma of the Esophagus1
2Active Not RecruitingTreatmentEarly-stage / Lung Cancer Non-Small Cell Cancer (NSCLC) / Resectable1
2Not Yet RecruitingTreatmentBreast Cancer1
2Not Yet RecruitingTreatmentMicrosatellite-stable Colorectal Cancer1
2RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2RecruitingTreatmentStage III Non-Small Cell Lung Cancer / Unresectable1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 18:31 / Updated on March 01, 2020 21:19

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates